Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeanann Vawter

Nurse Practitioner Gastonia, NC Nurse Practitioner

NPI 1043253776 CMS profile 11096342

924 Cox Road, Gastonia, NC 28052

Open in the dashboard

General payments

$97,024

345 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeanann Vawter of Gastonia, NC is reported in the CMS Open Payments database as having received $97,024 across 345 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,907 39
2024 General $14,752 55
2023 General $20,088 74
2022 General $35,573 79
2021 General $14,704 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeanann Vawter
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jeanann Vawter were reported at $11,907. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jeanann Vawter Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $14,704 $135 $40–$426 $132
2022 $35,573 $152 $48–$470 $149
2023 $20,088 $166 $54–$529 $160
2024 $14,752 $173 $55–$556 $164
2025 $11,907 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $79,547 131 payments
  2. Coloplast Corp $5,235 60 payments
  3. Axonics Modulation Technologies, Inc. $3,347 35 payments
  4. Teleflex LLC $2,266 27 payments
  5. Boston Scientific Corporation $1,661 16 payments
  6. Janssen Scientific Affairs, LLC $1,523 8 payments
  7. Myriad Genetic Laboratories, Inc. $712 10 payments
  8. Agiliti Surgical, Inc. $632 6 payments
  9. Medtronic, Inc. $343 5 payments
  10. Astellas Pharma US Inc $261 10 payments
  11. Other $1,497 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $62,900 44 payments
  2. Food and Beverage $17,576 252 payments
  3. Travel and Lodging $14,253 43 payments
  4. Consulting Fee $2,063 3 payments
  5. Education $233 3 payments
Products named General payments · program years 2021–2025
  1. ERLEADA $71,772 121 payments
  2. AKEEGA $11,507 23 payments
  3. RYBREVANT $8,776 13 payments
  4. CARVYKTI $8,776 13 payments
  5. Axonics r-SNM System $1,846 15 payments
  6. Axonics $1,731 22 payments
  7. Altis $1,202 11 payments
  8. Titan $1,094 11 payments
  9. UROLIFT $1,035 13 payments
  10. Coloplast TFL Drive $858 8 payments
  11. Other $8,422 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,405

Median for Nurse Practitioner: 389

Drug cost

$2,321,050

Median for Nurse Practitioner: $21,885

Branded share of claims

34.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 112 $1,747,698
Nubeqa Darolutamide Brand 26 $349,978
Myrbetriq Mirabegron Brand 146 $114,417
Gemtesa Vibegron Brand 25 $27,443
Methenamine Hippurate Generic 210 $21,080
Potassium Citrate Er Potassium Citrate Brand 70 $8,617
Mirabegron Er Mirabegron Brand 22 $8,563
Solifenacin Succinate Generic 167 $8,025
Premarin Estrogens, Conjugated Brand 18 $7,873
Tamsulosin Hcl Generic 510 $6,732

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$347,609

Of which drugs: $226,078

Medicare patients

708

Average age 75

Services billed

17,865

197 women, 511 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 37%
Ischemic heart disease 37%
Cancer 31%
Chronic kidney disease 30%
Atrial fibrillation 22%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 20 6,840 $139,908
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 34 306 $42,432
Injection, degarelix, 1 mg J9155 Office 14 6,800 $22,470

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $5,816
$5,816 112 —
AKEEGA
  • Janssen Biotech, Inc. $5,794
$5,794 — —
XTANDI
  • PFIZER INC. $40
$40 — —
BOTOX
  • AbbVie, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

345 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record